Sarepta Therapeutics (SRPT) Enterprise Value (2010 - 2026)

Sarepta Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$405.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 22.42% year-over-year to -$405.6 million in Q1 2026; TTM through Mar 2026 was -$405.6 million, a 22.42% increase from a year earlier, with the FY2025 full-year figure at -$939.6 million, up 14.26% from the prior year.
• Enterprise Value rose to -$405.6 million in Q1 2026 per SRPT's latest filing, from -$939.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$242.5 million in Q3 2024 and bottomed at -$2.1 billion in Q3 2022.
• The 5-year median for Enterprise Value is -$1.5 billion (2024), against an average of -$1.3 billion.
• Across the five-year window, Enterprise Value jumped 86.01% in 2024 and slumped 164.96% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$2.0 billion in 2022, then grew by 15.74% to -$1.7 billion in 2023, then soared by 34.62% to -$1.1 billion in 2024, then climbed by 14.26% to -$939.6 million in 2025, then soared by 56.84% to -$405.6 million in 2026.
• Per Business Quant, the three latest SRPT Enterprise Value figures stand at -$405.6 million (Q1 2026), -$939.6 million (Q4 2025), and -$642.5 million (Q3 2025).